Reading PDSB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PDSB free→Reading PDSB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PDSB free→QuarterlyIQ Insights · PDSB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
below. The Purchase Agreement contains customary representations, warranties and covenants by the Company and customary indemnification obligations of the Company, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), and restrictive covenants relating to indebtedness, liens and variable rate transactions, each as more fully described in the Prior 8-K. Promissory Note The Promissory Note was issued on the Closing Date with an aggregate face value of $6…
Creation of A Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure required by this
Entry into a Material Definitive Agreement. Closing of the Securities Purchase Agreement Transactions As previously disclosed in the Current Report on Form 8-K filed by PDS Biotechnology Corporation (the “Company”) with the Securities and Exchange Commission (the “SEC”) on May 1, 2026 (the “Prior 8-K”), on April 30, 2026 (the “Effective Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with YA II PN, LTD., a Cayman Islands exempt limited company (the…
relating to the issuance of the Promissory Note and the Warrant is included in
Material Modification to Rights of Security Holders. The disclosure required by this
Results of Operation and Financial Condition. On May 13, 2026, PDS Biotechnology Corporation (the “Company”) issued a press release announcing a business update and its financial results for the quarter ended March 31, 2026. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to be “furnished” and s…
related to the issuance of the Promissory Note and Warrant is included in
Termination of a Material Definitive Agreement. On the Effective Date, the Company delivered a redemption notice (each, a “ Redemption Notice ”) pursuant to which it irrevocably elected to prepay all of the outstanding principal amount under each of the Senior Secured Convertible Debentures (the “ Debentures ”), issued pursuant to that certain Securities Purchase Agreement by and among the Company, each of the buyers that are parties thereto and JGB Collateral LLC, a Delaware limited liabilit…
Creation of A Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure required by this item is included in
Entry into a Material Definitive Agreement. Securities Purchase Agreement On April 30, 2026 (the “ Effective Date ”), PDS Biotechnology Corporation, a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with YA II PN, LTD., a Cayman Islands exempt limited company (the “ Investor ”). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investor and the Investor agreed to purchase from the Company (i) a pro…
Results of Operation and Financial Condition. On March 30, 2026, PDS Biotechnology Corporation (the “Company”) issued a press release announcing a business update and its financial results for the year ended December 31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to be “furnished” and…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 25, 2026, PDS Biotechnology Corporation (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued lis…
Results of Operation and Financial Condition. On November 13, 2025, PDS Biotechnology Corporation (the “Company”) issued a press release announcing an update to its clinical programs and its financial results for the quarter ended September 30, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deem…
Results of Operations and Financial Condition. For the three month period ended September 30, 2025, the Company had approximately $26.2 million of cash and cash equivalents. This is derived from the Company’s internal books and records and is subject to the completion of financial closing procedures, final adjustments and other developments which may arise between now and the time the financial results for the quarter ended September 30, 2025 are finalized. Therefore, actual results may diffe…
Entry into a Material Definitive Agreement. On November 11, 2025, PDS Biotechnology Corporation, a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Purchase Agreement ”) with one or more investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”). The Purchase Agreement provides for the sale and issuance by the Company of an aggregate of: (i) 5,741,000 shares (the “ Shares ”) of the Company’s common stock, $0.00033 par value (the “ Common…
Results of Operation and Financial Condition. On August 13, 2025, PDS Biotechnology Corporation (the “Company”) issued a press release announcing an update to its clinical programs and its financial results for the quarter ended June 30, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to b…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan PDS Biotechnology Corporation (the “Company”) held its 2025 annual meeting of stockholders on June 11, 2025 (the “Annual Meeting”). As previously disclosed, on April 29, 2025, the Board of Directors of the Company adopted, subject to stockholder…
Results of Operation and Financial Condition. On May 14, 2025, PDS Biotechnology Corporation (the “Company”) issued a press release announcing an update to its clinical programs and its financial results for the quarter ended March 31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to be…
Termination of a Material Definitive Agreement The information provided in
Creation of A Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure required by this item is included in
Unregistered Sales of Equity Securities. The disclosure required by this
Entry into a Material Definitive Agreement. Securities Purchase Agreement On April 30, 2025, PDS Biotechnology Corporation, a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with each of the buyers that are parties thereto (each, including its successors and assigns, a “ Buyer ” and collectively, the “ Buyers ”) and JGB Collateral LLC, a Delaware limited liability company, as Collateral Agent (the “ Agent ”). Pursuant to the Pu…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 22, 2025, Sir Richard Sykes, a member of the Board of Directors (the “Board”) of PDS Biotechnology Corporation (the “Company”), notified the Company that he will retire and not stand for re-election as a director of the Company upon the expiration of his current term which expires at the Company’s 2025 Annual Meeting of Stockholders. Signa…
Results of Operation and Financial Condition. On March 27, 2025, PDS Biotechnology Corporation (the “Company”) issued a press release announcing an update to its clinical programs and its financial results for the year ended December 31, 2024. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to b…
Entry into a Material Definitive Agreement. On February 26, 2025, PDS Biotechnology Corporation, a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Purchase Agreement ”) with one or more investors (each, a “ Purchaser ” and collectively, the Purchasers). The Purchase Agreement provides for the sale and issuance by the Company of an aggregate of: (i) 6,396,787 shares (the “ Shares ”) of the Company’s common stock, $0.00033 par value (the “ Common Stoc…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.